VYGR Voyager Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1640266 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-19.8%
TTM net income YoY17.6%
TTM EPS YoY19.8%
Revenue 3-yr CAGR-45.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-450.1%
Net margin-416.3%
FCF margin-437.4%
EBITDA margin-435.3%
Returns
ROE-58.9%
ROA-44.9%
ROIC (approx.)-69.8%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets23.7%
Debt / equity0.00x
Current ratio6.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio2.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.01M | $3.17M | $2.59M | $15.34M | $13.37M | $5.20M | $6.47M | $6.28M |
| R&D expense | $24.37M | $22.04M | $24.60M | $35.95M | $35.87M | $31.33M | $31.53M | $35.58M |
| SG&A expense | $6.07M | $7.52M | $8.26M | $9.32M | $8.09M | $10.49M | $9.64M | $8.99M |
| Operating income | -$26.42M | -$26.39M | -$30.27M | -$29.93M | -$30.59M | -$36.62M | -$34.69M | -$38.30M |
| Pretax income | -$24.68M | -$24.45M | -$27.92M | -$27.42M | -$27.81M | -$33.37M | -$30.98M | -$33.90M |
| Income tax | $18,000 | $20,000 | $14,000 | $9,000 | $83,000 | $15,000 | $37,000 | $584,000 |
| Net income | -$24.69M | -$24.47M | -$27.94M | -$27.43M | -$27.89M | -$33.38M | -$31.02M | -$34.49M |
| EBITDA | -$25.59M | -$25.48M | -$29.34M | -$28.88M | -$29.66M | -$35.56M | -$33.68M | -$37.29M |
| EPS (basic) | -0.40 | -0.40 | -0.47 | — | -0.47 | -0.57 | -0.53 | — |
| EPS (diluted) | -0.40 | -0.40 | -0.47 | — | -0.47 | -0.57 | -0.53 | — |
| Weighted avg. shares (diluted) | 61.82M | 60.55M | 59.50M | — | 58.80M | 58.67M | 58.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $48.41M | $35.77M | $43.31M | $65.30M | $50.74M | $46.81M | $77.63M | $74.24M |
| Short-term investments | $58.40M | $80.57M | $98.17M | $131.15M | $163.81M | $171.65M | $161.26M | $195.32M |
| Receivables | $4.02M | $2.93M | $1.49M | $1.76M | $3.19M | $1.67M | $1.62M | $1.50M |
| Current assets | $114.43M | $125.23M | $146.98M | $202.69M | $219.59M | $227.89M | $245.21M | $276.81M |
| PP&E, net | $9.77M | $11.19M | $12.22M | $13.14M | $13.29M | $13.92M | $13.93M | $14.31M |
| Total assets | $177.05M | $197.75M | $219.32M | $252.28M | $288.31M | $322.10M | $353.24M | $393.05M |
| Current liabilities | $16.81M | $16.68M | $17.45M | $26.54M | $35.49M | $41.98M | $40.21M | $49.79M |
| Total liabilities | $41.94M | $43.38M | $45.66M | $56.20M | $68.49M | $78.16M | $80.54M | $93.29M |
| Shareholders' equity | $135.11M | $154.38M | $173.67M | $196.08M | $219.82M | $243.94M | $272.70M | $299.76M |
| Shares outstanding | 62.17M | 61.27M | 60.31M | 59.05M | 55.48M | 55.43M | 55.21M | 54.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.67M | -$25.84M | -$33.42M | -$30.26M | -$31.05M | -$33.26M | -$37.90M | -$14.53M |
| Capital expenditure | $0 | $0 | $14,000 | $626,000 | $207,000 | $1.10M | $658,000 | $155,000 |
| Free cash flow | -$19.67M | -$25.84M | -$33.43M | -$30.89M | -$31.25M | -$34.37M | -$38.55M | -$14.68M |
| Investing cash flow | $29.27M | $15.39M | $8.10M | $47.42M | $34.89M | $1.93M | $41.20M | -$27.20M |
| Financing cash flow | $3.03M | $2.91M | $3.33M | $136,000 | $85,000 | $513,000 | $82,000 | $574,000 |
| Depreciation & amortization | $836,000 | $908,000 | $932,000 | $1.05M | $932,000 | $1.06M | $1.01M | $1.01M |
| Stock-based compensation | $2.60M | $2.60M | $2.49M | $3.52M | $3.46M | $4.13M | $3.67M | $3.74M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.